U.S. flag

An official website of the United States government

NM_004985.5(KRAS):c.35G>A (p.Gly12Asp) AND Cerebral arteriovenous malformation

Germline classification:
Pathogenic (3 submissions)
Last evaluated:
Nov 3, 2023
Review status:
1 star out of maximum of 4 stars
criteria provided, single submitter
Somatic classification
of clinical impact:
None
Review status:
(0/4) 0 stars out of maximum of 4 stars
no assertion criteria provided
Somatic classification
of oncogenicity:
None
Review status:
(0/4) 0 stars out of maximum of 4 stars
no assertion criteria provided
Record status:
current
Accession:
RCV000585796.11

Allele description [Variation Report for NM_004985.5(KRAS):c.35G>A (p.Gly12Asp)]

NM_004985.5(KRAS):c.35G>A (p.Gly12Asp)

Gene:
KRAS:KRAS proto-oncogene, GTPase [Gene - OMIM - HGNC]
Variant type:
single nucleotide variant
Cytogenetic location:
12p12.1
Genomic location:
Preferred name:
NM_004985.5(KRAS):c.35G>A (p.Gly12Asp)
HGVS:
  • NC_000012.12:g.25245350C>T
  • NG_007524.2:g.10654G>A
  • NM_001369786.1:c.35G>A
  • NM_001369787.1:c.35G>A
  • NM_004985.5:c.35G>AMANE SELECT
  • NM_033360.4:c.35G>A
  • NP_001356715.1:p.Gly12Asp
  • NP_001356716.1:p.Gly12Asp
  • NP_004976.2:p.Gly12Asp
  • NP_203524.1:p.Gly12Asp
  • LRG_344t1:c.35G>A
  • LRG_344t2:c.35G>A
  • LRG_344:g.10654G>A
  • LRG_344p1:p.Gly12Asp
  • LRG_344p2:p.Gly12Asp
  • NC_000012.11:g.25398284C>T
  • NG_007524.1:g.10571G>A
  • NM_004985.3:c.35G>A
  • NM_004985.4:c.35G>A
  • NM_033360.2:c.35G>A
  • NM_033360.3:c.35G>A
  • P01116:p.Gly12Asp
Protein change:
G12D; GLY12ASP
Links:
UniProtKB: P01116#VAR_016026; OMIM: 190070.0005; OMIM: 190070.0025; dbSNP: rs121913529
NCBI 1000 Genomes Browser:
rs121913529
Molecular consequence:
  • NM_001369786.1:c.35G>A - missense variant - [Sequence Ontology: SO:0001583]
  • NM_001369787.1:c.35G>A - missense variant - [Sequence Ontology: SO:0001583]
  • NM_004985.5:c.35G>A - missense variant - [Sequence Ontology: SO:0001583]
  • NM_033360.4:c.35G>A - missense variant - [Sequence Ontology: SO:0001583]
Functional consequence:
effect on catalytic protein function [Variation Ontology: 0008]
Observations:
5

Condition(s)

Name:
Cerebral arteriovenous malformation (BAVM)
Synonyms:
CEREBRAL ARTERIOVENOUS MALFORMATIONS; Arteriovenous malformations of the brain
Identifiers:
MONDO: MONDO:0007154; MedGen: C0917804; Orphanet: 46724; OMIM: 108010; Human Phenotype Ontology: HP:0002408

Recent activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...

Assertion and evidence details

Submission AccessionSubmitterReview Status
(Assertion method)
Clinical Significance
(Last evaluated)
OriginMethodCitations
SCV000693723OMIM
no assertion criteria provided
Pathogenic
(Mar 6, 2018)
somaticliterature only

PubMed (1)
[See all records that cite this PMID]

SCV000992585Arin Greene Laboratory, Boston Children's Hospital, Harvard Medical School
no assertion criteria provided
Pathogenicsomaticresearch

PubMed (1)
[See all records that cite this PMID]

SCV004176950Clinical Genomics Laboratory, Washington University in St. Louis
criteria provided, single submitter

(ACMG Guidelines, 2015)
Pathogenic
(Nov 3, 2023)
somaticclinical testing

PubMed (1)
[See all records that cite this PMID]

Summary from all submissions

EthnicityOriginAffectedIndividualsFamiliesChromosomes testedNumber TestedFamily historyMethod
not providedsomaticyes5not providednot providednot providednot providedclinical testing, research
not providedsomaticnot providednot providednot providednot providednot providednot providedliterature only

Citations

PubMed

Nothing to display

See all PubMed Citations (3)

Details of each submission

From OMIM, SCV000693723.1

#EthnicityIndividualsChromosomes TestedFamily HistoryMethodCitations
1not providednot providednot providednot providedliterature only PubMed (1)

Description

Using exome DNA sequencing and droplet digital PCR analysis, Nikolaev et al. (2018) identified a gly12-to-asp (G12D, c.35G-A) mutation in a total of 32 of 72 arteriovenous malformations of the brain (BAVM; 108010), and in none of 21 paired blood samples. Patient samples included 39 from a main study group and 33 from an independent validation group. This and the G12V variant (190070.0026) were present in 2.4 to 4.0% of the sequence reads per sample. The G12D mutation drove MAPK-ERK activity in endothelial cells.

#SampleMethodObservation
OriginAffectedNumber testedTissuePurposeMethodIndividualsAllele frequencyFamiliesCo-occurrences
1somaticnot providednot providednot providednot providednot providednot providednot providednot provided

From Arin Greene Laboratory, Boston Children's Hospital, Harvard Medical School, SCV000992585.1

#EthnicityIndividualsChromosomes TestedFamily HistoryMethodCitations
1not provided1not providednot providedresearch PubMed (1)
2not provided1not providednot providedresearch PubMed (1)
3not provided1not providednot providedresearch PubMed (1)
4not provided1not providednot providedresearch PubMed (1)
5not provided1not providednot providedresearch PubMed (1)
#SampleMethodObservation
OriginAffectedNumber testedTissuePurposeMethodIndividualsAllele frequencyFamiliesCo-occurrences
1somaticyesnot providednot providednot provided1not providednot providednot provided
2somaticyesnot providednot providednot provided1not providednot providednot provided
3somaticyesnot providednot providednot provided1not providednot providednot provided
4somaticyesnot providednot providednot provided1not providednot providednot provided
5somaticyesnot providednot providednot provided1not providednot providednot provided

From Clinical Genomics Laboratory, Washington University in St. Louis, SCV004176950.1

#EthnicityIndividualsChromosomes TestedFamily HistoryMethodCitations
1not providednot providednot providednot providedclinical testing PubMed (1)

Description

The KRAS c.35G>A (p.Gly12Asp) variant was identified at an allelic fraction consistent with somatic origin. This variant has been reported in multiple individuals affected with vascular malformations including numerous individuals with brain arteriovenous malformations (Nikolaev SI et al., PMID: 29298116; Lihua J et al., PMID: 29381910; Al-Olabi et al., PMID: 29461977; Goss JA et al., PMID: 31486960; Schmidt FV et al., PMID: 34114335; Mitchell BJ et al., PMID: 30394973). This variant has been reported in the ClinVar database as a pathogenic/likely pathogenic variant in both a somatic and germline state by multiple submitters (ClinVar ID: 12582) and in numerous cancer cases as a somatic variant in the cancer database COSMIC (COMIC ID: COSV55497369). This variant is only observed on 2/152,128 alleles in the general population (gnomAD v.3.1.2), indicating it is not a common variant. The KRAS c.35G>A (p.Gly12Asp) variant resides within the P-loop region of KRAS that is defined as a critical functional domain (Gelb BD et al., PMID: 29493581). Computational predictors indicate that the variant is damaging, evidence that correlates with impact to KRAS function. In support of this prediction, functional studies show that this variant activates mitogen-activated protein kinase kinase 1 signaling pathway, leading to the formation of vascular malformation (Cistea IC et al., PMID: 23059812; Fish JE et al., PMID: 32552404; Janardhan HP et al., PMID: 32405640). The KRAS gene is defined by the ClinGen's RASopathies expert panel as a gene that has a low rate of benign missense variation and where pathogenic missense variants are a common mechanism of disease (Gelb BD et al., PMID: 29493581). Based on an internally developed protocol informed by the ACMG/AMP guidelines (Richards S et al., PMID: 25741868) and gene-specific practices from the ClinGen Criteria Specification Registry, the KRAS c.35G>A (p.Gly12Asp) variant is classified as pathogenic.

#SampleMethodObservation
OriginAffectedNumber testedTissuePurposeMethodIndividualsAllele frequencyFamiliesCo-occurrences
1somaticyesnot providednot providednot providednot providednot providednot providednot provided

Last Updated: Nov 18, 2024